Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses

Virus Research

Volumn 162, Issue 1-2, 2011, Pages 148-161

  Grant Klein, Rebecca J ^a   Altamura, Louis A ^a   Schmaljohn, Connie S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Ebolavirus; Filovirus; Lassa virus; Marburgvirus; Recombinant DNA vaccine

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; DNA VACCINE; FATTY ACID BINDING PROTEIN; FILOVIRUS VACCINE; LASSA VIRUS VACCINE; NUCLEOCAPSID PROTEIN; PLASMID DNA; RECOMBINANT DNA; RECOMBINANT VACCINE; RECOMBINANT VACCINIA VIRUS VACCINE; RECOMBINANT VESICULAR STOMATITIS VIRUS VACCINE; RIBAVIRIN; RNA POLYMERASE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VENEZUELAN EQUINE ENCEPHALITIS VIRUS REPLICON VACCINE; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

DISEASE SEVERITY; EBOLA VIRUS; EPIDEMIC; FEVER; FILOVIRUS; HEADACHE; HUMAN; LASSA VIRUS; LUNG EDEMA; MALAISE; MARBURG VIRUS; NONHUMAN; PRIORITY JOURNAL; RAVN VIRUS; RESPIRATORY DISTRESS; REVIEW; SORE THROAT; VACCINIA VIRUS; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; EBOLAVIRUS; GENETIC VARIATION; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LASSA FEVER; LASSA VIRUS; MARBURG VIRUS DISEASE; MARBURGVIRUS; PLASMIDS; PUBLIC HEALTH; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VESICULOVIRUS; VIRAL VACCINES; VIRUS REPLICATION;

ANIMALIA; EBOLA VIRUS; LASSA VIRUS; MARBURGVIRUS;

EID: 81555204355     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.09.005     Document Type: Review

References (137)

1. Agnihothram S.S., York J., Nunberg J.H. Role of the stable signal peptide and cytoplasmic domain of G2 in regulating intracellular transport of the Junin virus envelope glycoprotein complex. J. Virol. 2006, 80(11):5189-5198.
2. Albarino C.G., Bird B.H., Chakrabarti A.K., Dodd K.A., Erickson B.R., Nichol S.T. Efficient rescue of recombinant Lassa virus reveals the influence of S segment noncoding regions on virus replication and virulence. J. Virol. 2011, 85(8):4020-4024.
3. Alibek K. The Soviet Union's anti-agricultural biological weapons. Ann. N.Y. Acad. Sci. 1999, 894:18-19.
4. Amblard J., Obiang P., Edzang S., Prehaud C., Bouloy M., le Guenno B. Identification of the ebola virus in Gabon in 1994. Lancet (New York) 1997, 349(9046):181-182.
5. Baize S., Marianneau P., Georges-Courbot M.C., Deubel V. Recent advances in vaccines against viral haemorrhagic fevers. Curr. Opin. Infect. Dis. 2001, 14(5):513-518.
6. Baize S., Marianneau P., Loth P., Reynard S., Journeaux A., Chevallier M., Tordo N., Deubel V., Contamin H. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 2009, 83(11):5890-5903.
7. Baron R.C., McCormick J.B., Zubeir O.A. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull. World Health Organ. 1983, 61(6):997-1003.
8. Barouch D.H., Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 2005, 16(2):149-156.
9. Baskerville A., Bowen E.T., Platt G.S., McArdell L.B., Simpson D.I. The pathology of experimental Ebola virus infection in monkeys. J. Pathol. 1978, 125(3):131-138.
10. Bastin R., Charmot G., Frottier J. Infectious and parasitic diseases Survey of the current status in 1977. Rev. Prat. 1977, 27(29):1833-1858.
11. Bausch D.G., Geisbert T.W. Development of vaccines for Marburg hemorrhagic fever. Expert Rev. Vaccines 2007, 6(1):57-74.
12. Bausch D.G., Nichol S.T., Muyembe-Tamfum J.J., Borchert M., Rollin P.E., Sleurs H., Campbell P., Tshioko F.K., Roth C., Colebunders R., Pirard P., Mardel S., Olinda L.A., Zeller H., Tshomba A., Kulidri A., Libande M.L., Mulangu S., Formenty P., Grein T., Leirs H., Braack L., Ksiazek T., Zaki S., Bowen M.D., Smit S.B., Leman P.A., Burt F.J., Kemp A., Swanepoel R. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med. 2006, 355(9):909-919.
13. Bengtsson E. Green monkey disease-a current epidemic hemorrhagic fever. Lakartidningen 1976, 73(46):3969.
14. Benit L., Dessen P., Heidmann T. Identification, phylogeny, and evolution of retroviral elements based on their envelope genes. J. Virol. 2001, 75(23):11709-11719.
15. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287(18):2391-2405.
16. Bosio C.M., Aman M.J., Grogan C., Hogan R., Ruthel G., Negley D., Mohamadzadeh M., Bavari S., Schmaljohn A. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 2003, 188(11):1630-1638.
17. Bosio C.M., Moore B.D., Warfield K.L., Ruthel G., Mohamadzadeh M., Aman M.J., Bavari S. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004, 326(2):280-287.
18. Botten J., Whitton J.L., Barrowman P., Sidney J., Whitmire J.K., Alexander J., Kotturi M.F., Sette A., Buchmeier M.J. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J. Virol. 2010, 84(19):9947-9956.
19. Bowen M.D., Rollin P.E., Ksiazek T.G., Hustad H.L., Bausch D.G., Demby A.H., Bajani M.D., Peters C.J., Nichol S.T. Genetic diversity among Lassa virus strains. J. Virol. 2000, 74(15):6992-7004.
20. Bradfute S.B., Braun D.R., Shamblin J.D., Geisbert J.B., Paragas J., Garrison A., Hensley L.E., Geisbert T.W. Lymphocyte death in a mouse model of Ebola virus infection. J. Infect. Dis. 2007, 196(SUPPL. 2):S296-S304.
21. Bradfute S.B., Warfield K.L., Bavari S. Functional CD8+ T cell responses in lethal Ebola virus infection. J. Immunol. 2008, 180(6):4058-4066.
22. Branch C.S.P. Marburg hemorrhagic fever: known cases and outbreaks of Marburg hemorrhagic fever, in chronological order. CDC On-line Database 2010.
23. Branco L.M., Grove J.N., Geske F.J., Boisen M.L., Muncy I.J., Magliato S.A., Henderson L.A., Schoepp R.J., Cashman K.A., Hensley L.E., Garry R.F. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J. 2010, 7:279.
24. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 1998, 178(3):651-661.
25. Bray M., Hatfill S., Hensley L., Huggins J.W. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 2001, 125(4):243-253.
26. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S., Moshkoff D., Zapata J., Tikhonov I., Patterson J., Carrion R., Ticer A., Brasky K., Lukashevich I.S. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345(2):299-304.
27. Buchmeier M.J., De la Torre J.C., Peters C.J. Arenaviridae: the viruses and their replication. Fileds Virology, vol. 2 2007, 1791-1882. Lippincott Williams, Wilkins, Philadelphia, PA. D.M. Knipe, P.M. Howley (Eds.).
28. Callis R.T., Jahrling P.B., DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am. J. Trop. Med. Hyg. 1982, 31(5):1038-1045.
29. CDC Follow-up on Viral Hemorrhagic Fever-Zaire 1976, CDC, United Kingdom.
30. CDC. 1990 Update: Filovirus Infection in Animal Handlers. Morbidity and Mortality Weekly Report (Atlanta) 39(24), 404-405.
31. CDC. 2008 National task force situation report #20.
32. Conner M.E., Zarley C.D., Hu B., Parsons S., Drabinski D., Greiner S., Smith R., Jiang B., Corsaro B., Barniak V., Madore H.P., Crawford S., Estes M.K. Virus-like particles as a rotavirus subunit vaccine. J. Infect. Dis. 1996, 174(Suppl 1):S88-S92.
33. Cornu T.I., Feldmann H., de la Torre J.C. Cells expressing the RING finger Z protein are resistant to arenavirus infection. J. Virol. 2004, 78(6):2979-2983.
34. Cummins D., McCormick J.B., Bennett D., Samba J.A., Farrar B., Machin S.J., Fisher-Hoch S.P. Acute sensorineural deafness in Lassa fever. JAMA 1990, 264(16):2093-2096.
35. Dye J.M., Barth J., Kuehne A. Post-exposure transfer of immunoglobulin G from convalescent survivors protects rhesus macaques form Marburg virus. 5th International Symposium on Filoviruses 2010.
36. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. 2006, 6(4):203-214.
37. Falzarano D., Geisbert T.W., Feldmann H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev. Vaccines 2011, 10(1):63-77.
38. Feldmann H., Geisbert T., Jahrling P., et al. Filoviridae. Virus Taxonomy: Eighth Report of the International Committee on the Taxonomy of Viruses 2005, Elsevier, San Diego, CA. M.M.C.M. Fauquet, J. Maniloff, U. Desselberger, L.A. Ball (Eds.).
39. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Stroher U., Grolla A., Bray M., Fritz E.A., Fernando L., Feldmann F., Hensley L.E., Geisbert T.W. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007, 3(1):e2.
40. Feldmann H., Slenczka W., Klenk H.D. Emerging and reemerging of filoviruses. Arch. Virol. SUPPL. 1996, 11:77-100.
41. Fisher-Hoch S.P., Hutwagner L., Brown B., McCormick J.B. Effective vaccine for lassa fever. J. Virol. 2000, 74(15):6777-6783.
42. Fisher-Hoch S.P., McCormick J.B. Towards a human Lassa fever vaccine. Rev. Med. Virol. 2001, 11(5):331-341.
43. Fisher-Hoch S.P., McCormick J.B. Lassa fever vaccine. Expert Rev. Vaccines 2004, 3(2):189-197.
44. Fisher-Hoch S.P., Platt G.S., Neild G.H., Southee T., Baskerville A., Raymond R.T., Lloyd G., Simpson D.I. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J. Infect. Dis. 1985, 152(5):887-894.
45. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., Giles-Davis W., Wilson J.M., Ertl H.C. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 2003, 170(3):1416-1422.
46. Flatz L., Rieger T., Merkler D., Bergthaler A., Regen T., Schedensack M., Bestmann L., Verschoor A., Kreutzfeldt M., Bruck W., Hanisch U.K., Gunther S., Pinschewer D.D. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 2010, 6(3):e1000836.
47. Gallaher W.R., DiSimone C., Buchmeier M.J. The viral transmembrane superfamily: possible divergence of arenavirus and filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol. 2001, 1:1.
48. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., Volchkov V., Klenk H.D., Feldmann H., Stroher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 2004, 78(10):5458-5465.
49. Geisbert T.W., Bailey M., Geisbert J.B., Asiedu C., Roederer M., Grazia-Pau M., Custers J., Jahrling P., Goudsmit J., Koup R., Sullivan N.J. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 2010, 84(19):10386-10394.
50. Geisbert T.W., Bailey M., Hensley L., Asiedu C., Geisbert J., Stanley D., Honko A., Johnson J., Mulangu S., Pau M.G., Custers J., Vellinga J., Hendriks J., Jahrling P., Roederer M., Goudsmit J., Koup R., Sullivan N.J. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 2011, 85(9):4222-4233.
51. Geisbert T.W., Bausch D.G., Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev. Med. Virol. 2010, 20(6):344-357.
52. Geisbert T.W., Daddario-Dicaprio K.M., Geisbert J.B., Reed D.S., Feldmann F., Grolla A., Stroher U., Fritz E.A., Hensley L.E., Jones S.M., Feldmann H. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008, 26(52):6894-6900.
53. Geisbert T.W., Daddario-Dicaprio K.M., Lewis M.G., Geisbert J.B., Grolla A., Leung A., Paragas J., Matthias L., Smith M.A., Jones S.M., Hensley L.E., Feldmann H., Jahrling P.B. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008, 4(11):e1000225.
54. Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J. Virol. 2009, 83(14):7296-7304.
55. Geisbert T.W., Hensley L.E., Gibb T.R., Steele K.E., Jaax N.K., Jahrling P.B. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 2000, 80(2):171-186.
56. Geisbert T.W., Hensley L.E., Larsen T., Young H.A., Reed D.S., Geisbert J.B., Scott D.P., Kagan E., Jahrling P.B., Davis K.J. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 2003, 163(6):2347-2370.
57. Geisbert T.W., Jaax N.K. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct. Pathol. 1998, 22(1):3-17.
58. Geisbert T.W., Jahrling P.B. Use of immunoelectron microscopy to show Ebola virus during the 1989 United States epizootic. J. Clin. Pathol. 1990, 43(10):813-816.
59. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Stroher U., Fernando L., Daddario K.M., Guttieri M.C., Mothe B.R., Larsen T., Hensley L.E., Jahrling P.B., Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005, 2(6):e183.
60. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 2002, 8(5):503-507.
61. Gibb T.R., Bray M., Geisbert T.W., Steele K.E., Kell W.M., Davis K.J., Jaax N.K. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 2001, 125(4):233-242.
62. Gonzalez J.P., Pourrut X., Leroy E. Ebolavirus and other filoviruses. Curr. Top. Microbiol. Immunol. 2007, 315:363-387.
63. Groen J., van den Hoogen B.G., Burghoorn-Maas C.P., Fooks A.R., Burton J., Clegg C.J., Zeller H., Osterhaus A.D. Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins. Microbes Infect. 2003, 5(5):379-385.
64. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
65. Hacker J.K., Hardy J.L. Adsorptive endocytosis of California encephalitis virus into mosquito and mammalian cells: a role for G1. Virology 1997, 235(1):40-47.
66. Hensley L.E., Smith M.A., Geisbert J.B., Fritz E.A., Daddario-DiCaprio K.M., Larsen T., Geisbert T.W. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 2011, 8:205.
67. Hevey M., Negley D., Pushko P., Smith J., Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998, 251(1):28-37.
68. Ikegami T., Niikura M., Saijo M., Miranda M.E., Calaor A.B., Hernandez M., Acosta L.P., Manalo D.L., Kurane I., Yoshikawa Y., Morikawa S. Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoprotein. Clin. Diagn. Lab. Immunol. 2003, 10(4):552-557.
69. Ikegami T., Saijo M., Niikura M., Miranda M.E., Calaor A.B., Hernandez M., Manalo D.L., Kurane I., Yoshikawa Y., Morikawa S. Immunoglobulin G enzyme-linked immunosorbent assay using truncated nucleoproteins of Reston Ebola virus. Epidemiol. Infect. 2003, 130(3):533-539.
70. Jahrling P.B., Geisbert T.W., Dalgard D.W., Johnson E.D., Ksiazek T.G., Hall W.C., Peters C.J. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990, 335(8688):502-505.
71. Jahrling P.B., Hesse R.A., Eddy G.A., Johnson K.M., Callis R.T., Stephen E.L. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 1980, 141(5):580-589.
72. Jahrling P.B., Smith S., Hesse R.A., Rhoderick J.B. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 1982, 37(2):771-778.
73. Jiang X., Dalebout T.J., Bredenbeek P.J., Carrion R., Brasky K., Patterson J., Goicochea M., Bryant J., Salvato M.S., Lukashevich I.S. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 2011, 29(6):1248-1257.
74. Johnson E.D., Johnson B.K., Silverstein D., Tukei P., Geisbert T.W., Sanchez A.N., Jahrling P.B. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. SUPPL. 1996, 11:101-114.
75. Johnson K.M., Webb P.A., Lange J.V., Murphy F.A. Isolation and partial characterisation of a new virus causing causing haemorrhagic fever in Zaire. Lancet (New York) 1977, i(8011):569-571.
76. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling P.B., Geisbert T.W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005, 11(7):786-790.
77. Kash J.C., Muhlberger E., Carter V., Grosch M., Perwitasari O., Proll S.C., Thomas M.J., Weber F., Klenk H.D., Katze M.G. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 2006, 80(6):3009-3020.
78. Khan A.S., Tshioko F.K., Heymann D.L., Le Guenno B., Nabeth P., Kerstiens B., Fleerackers Y., Kilmarx P.H., Rodier G.R., Nkuku O., Rollin P.E., Sanchez A., Zaki S.R., Swanepoel R., Tomori O., Nichol S.T., Peters C.J., Muyembe-Tamfum J.J., Ksiazek T.G. The reemergence of Ebola hemorrhagic fever Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J. Infect. Dis. 1999, 179(Suppl 1):S76-S86.
79. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., Jones S., Wilson J.M. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006, 346(2):394-401.
80. Kuhn J.H. Filoviruses 2008, Springer-Verlag/Wien, Austria. H. Calisher (Ed.).
81. Kuhn J.H., Becker S., Ebihara H., Geisbert T.W., Johnson K.M., Kawaoka Y., Lipkin W.I., Negredo A.I., Netesov S.V., Nichol S.T., Palacios G., Peters C.J., Tenorio A., Volchkov V.E., Jahrling P.B. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch. Virol. 2010, 155(12):2083-2103.
82. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat. Rev. Genet. 2008, 9(10):776-788.
83. Kuzmin I.V., Niezgoda M., Franka R., Agwanda B., Markotter W., Breiman R.F., Shieh W.J., Zaki S.R., Rupprecht C.E. Marburg virus in fruit bat, Kenya. Emerg. Infect. Dis. 2010, 16(2):352-354.
84. Le Guenno B., Formenty P., Boesch C. Ebola virus outbreaks in the Ivory Coast and Liberia, 1994-1995. Curr. Top. Microbiol. Immunol. 1999, 235:77-84.
85. Lenz O., ter Meulen J., Klenk H.D., Seidah N.G., Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(22):12701-12705.
86. Lukashevich I.S. Generation of reassortants between African arenaviruses. Virology 1992, 188(2):600-605.
87. Lukashevich I.S., Carrion R., Salvato M.S., Mansfield K., Brasky K., Zapata J., Cairo C., Goicochea M., Hoosien G.E., Ticer A., Bryant J., Davis H., Hammamieh R., Mayda M., Jett M., Patterson J. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008, 26(41):5246-5254.
88. Lukashevich I.S., Patterson J., Carrion R., Moshkoff D., Ticer A., Zapata J., Brasky K., Geiger R., Hubbard G.B., Bryant J., Salvato M.S. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 2005, 79(22):13934-13942.
89. MacNeil A., Farnon E.C., Wamala J., Okware S., Cannon D.L., Reed Z., Towner J.S., Tappero J.W., Lutwama J., Downing R., Nichol S.T., Ksiazek T.G., Rollin P.E. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection Uganda. Emerg. Infect. Dis. 2010, 16(12):1969-1972.
90. Mahanty S., Hutchinson K., Agarwal S., McRae M., Rollin P.E., Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 2003, 170(6):2797-2801.
91. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., Roederer M., Koup R.A., Bailer R.T., Chakrabarti B.K., Bailey M.A., Gomez P.L., Andrews C.A., Moodie Z., Gu L., Stein J.A., Nabel G.J., Graham B.S. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccine Immunol. 2006, 13(11):1267-1277.
92. McClain D.J., Summers P.L., Harrison S.A., Schmaljohn A.L., Schmaljohn C.S. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 2000, 60(1):77-85.
93. McCormick, J.B., Fisher-Hock, S., Horvitz, L.A. (1999) Level 4-Virus Hunters of the CDC. Update Edition, edited by T. Publishing, Atlanta, GA, U.S.A.
94. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Belmont-Williams R. Lassa fever Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314(1):20-26.
95. McCormick J.B., Mitchell S.W., Kiley M.P., Ruo S., Fisher-Hoch S.P. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J. Med. Virol. 1992, 37(1):1-7.
96. Mohamadzadeh M., Chen L., Schmaljohn A.L. How Ebola and Marburg viruses battle the immune system. Nat. Rev. Immunol. 2007, 7(7):556-567.
97. Nardin A., Sutherland W.M., Hevey M., Schmaljohn A., Taylor R.P. Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes. J. Immunol. Methods 1998, 211(1-2):21-31.
98. Perez M., Craven R.C., de la Torre J.C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(22):12978-12983.
99. Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T., Barrera Oro J.G. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 1987, 134:5-68.
100. Pratt W.D., Wang D., Nichols D.K., Luo M., Woraratanadharm J., Dye J.M., Holman D.H., Dong J.Y. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin. Vaccine Immunol. 2010, 17(4):572-581.
101. Pushko P., Bray M., Ludwig G.V., Parker M., Schmaljohn A., Sanchez A., Jahrling P.B., Smith J.F. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19(1):142-153.
102. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 2001, 75(23):11677-11685.
103. Richardson J.S., Dekker J.D., Croyle M.A., Kobinger G.P. Recent advances in Ebolavirus vaccine development. Hum. Vaccine 2010, 6(6):439-449.
104. Richardson J.S., Yao M.K., Tran K.N., Croyle M.A., Strong J.E., Feldmann H., Kobinger G.P. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009, 4(4):e5308.
105. Riemenschneider J., Garrison A., Geisbert J., Jahrling P., Hevey M., Negley D., Schmaljohn A., Lee J., Hart M.K., Vanderzanden L., Custer D., Bray M., Ruff A., Ivins B., Bassett A., Rossi C., Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003, 21(25-26):4071-4080.
106. Rodriguez-Carreno M.P., Nelson M.S., Botten J., Smith-Nixon K., Buchmeier M.J., Whitton J.L. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 2005, 335(1):87-98.
107. Saijo M., Niikura M., Morikawa S., Ksiazek T.G., Meyer R.F., Peters C.J., Kurane I. Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins. J. Clin. Microbiol. 2001, 39(1):1-7.
108. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., Gorgone D.A., Beaudry K.R., Svehla K., Welcher B., Chakrabarti B.K., Huang Y., Yang Z.Y., Mascola J.R., Nabel G.J., Letvin N.L. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 2005, 79(10):6516-6522.
109. Schmaljohn C., Vanderzanden L., Bray M., Custer D., Meyer B., Li D., Rossi C., Fuller D., Fuller J., Haynes J., Huggins J. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J. Virol. 1997, 71(12):9563-9569.
110. Siegert R., Shu H.L., Slenczka W. Detection of the " Marburg Virus" in patients. Ger. Med. Mon. 1968, 13(11):521-524.
111. Smith D.H., Johnson B.K., Isaacson M., Swanapoel R., Johnson K.M., Killey M., Bagshawe A., Siongok T., Keruga W.K. Marburg-virus disease in Kenya. Lancet 1982, 1(8276):816-820.
112. Strecker T., Maisa A., Daffis S., Eichler R., Lenz O., Garten W. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol. J. 2006, 3:93.
113. Strobel E., Schmidt H.-U. A concept for blood supply in patients with highly contagious, life-threatening diseases. Transfus. Med. Hemother. 2004, 31(1):17-20.
114. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., Koup R.A., Jahrling P.B., Nabel G.J. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424(6949):681-684.
115. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408(6812):605-609.
116. Swanepoel R., Smit S.B., Rollin P.E., Formenty P., Leman P.A., Kemp A., Burt F.J., Grobbelaar A.A., Croft J., Bausch D.G., Zeller H., Leirs H., Braack L.E., Libande M.L., Zaki S., Nichol S.T., Ksiazek T.G., Paweska J.T. Studies of reservoir hosts for Marburg virus. Emerg. Infect. Dis. 2007, 13(12):1847-1851.
117. Swenson D.L., Wang D., Luo M., Warfield K.L., Woraratanadharm J., Holman D.H., Dong J.Y., Pratt W.D. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 2008, 15(3):460-467.
118. Swenson D.L., Warfield K.L., Negley D.L., Schmaljohn A., Aman M.J., Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005, 23(23):3033-3042.
119. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol. Ther. 2004, 10(4):616-629.
120. Taylor D.J., Leach R.W., Bruenn J. Filoviruses are ancient and integrated into mammalian genomes. BMC Evol. Biol. 2010, 10:193.
121. Timen A., Koopmans M.P., Vossen A.C., van Doornum G.J., Gunther S., van den Berkmortel F., Verduin K.M., Dittrich S., Emmerich P., Osterhaus A.D., van Dissel J.T., Coutinho R.A. Response to imported case of Marburg hemorrhagic fever, The Netherland. Emerg. Infect. Dis. 2009, 15(8):1171-1175.
122. Towner J.S., Khristova M.L., Sealy T.K., Vincent M.J., Erickson B.R., Bawiec D.A., Hartman A.L., Comer J.A., Zaki S.R., Stroher U., Gomes da Silva F., del Castillo F., Rollin P.E., Ksiazek T.G., Nichol S.T. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 2006, 80(13):6497-6516.
123. Towner J.S., Pourrut X., Albarino C.G., Nkogue C.N., Bird B.H., Grard G., Ksiazek T.G., Gonzalez J.P., Nichol S.T., Leroy E.M. Marburg virus infection detected in a common African bat. PLoS One 2007, 2(1):e764.
124. Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ 2009, 338:b1223.
125. Vanderzanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., Jahrling P., Huggins J., Schmaljohn A., Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998, 246(1):134-144.
126. Walker D.H., Johnson K.M., Lange J.V., Gardner J.J., Kiley M.P., McCormick J.B. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus Mozambique virus. J. Infect. Dis. 1982, 146(3):360-368.
127. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., Aman M.J., Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(26):15889-15894.
128. Warfield K.L., Swenson D.L., Demmin G., Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert Rev. Vaccines 2005, 4(3):429-440.
129. Warfield K.L., Swenson D.L., Negley D.L., Schmaljohn A.L., Aman M.J., Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004, 22(25-26):3495-3502.
130. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 2007, 196(Suppl 2):S430-S437.
131. Whitfield A.E., Ullman D.E., German T.L. Tomato spotted wilt virus glycoprotein G(C) is cleaved at acidic pH. Virus Res. 2005, 110(1-2):183-186.
132. WHO Marburgvirus disease: South Africa. World Health Organiz.: Weekly Epidemiol. Record 1975, 50(12):124-125.
133. WHO Marburg haemorrhagic fever, Uganda. Weekly Epidemiol. Record 2007, 82(33):297-298.
134. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., Wilson J.M., Ertl H.C. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 2002, 76(6):2667-2675.
135. York J., Nunberg J.H. Role of the stable signal peptide of Junin arenavirus envelope glycoprotein in pH-dependent membrane fusion. J. Virol. 2006, 80(15):7775-7780.
136. York J., Nunberg J.H. Distinct requirements for signal peptidase processing and function in the stable signal peptide subunit of the Junin virus envelope glycoprotein. Virology 2007, 359(1):72-81.
137. Zaki S.R., Goldsmith C.S. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol. 1999, 235:97-116.